You are viewing the site in preview mode
Skip to main content
|
Factors
|
No of patients with teicoplanin initial Cmin ≥20 μg/mL (%)
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
Patients with factor
|
Patients without factor
|
Crude odds ratio (95%CI)
|
P-value
|
Adjusted odds ratio (95%CI)
|
P-value
|
|---|
|
Enhanced high loading dose regimen
|
117/149 (78.5%)
|
150/363 (41.3%)
|
5.19 (3.33–8.089)
|
< 0.001
|
7.75 (4.62–12.99)
|
< 0.001
|
|
Sex (male)
|
161/318 (50.6%)
|
106/194 (54.6%)
|
0.85 (0.60–1.22)
|
0.378
| | |
|
Age (> 65 years)
|
162/318 (50.9%)
|
105/194 (54.1%)
|
0.88 (0.62–1.26)
|
0.485
| | |
|
Body mass index< 18.5
|
59/124 (47.6%)
|
208/388 (53.6%)
|
0.79 (0.52–1.18)
|
0.242
| | |
|
Body mass index ≥25
|
47/74 (63.5%)
|
220/438 (50.2%)
|
1.73 (1.04–2.87)
|
0.034
|
2.33 (1.24–4.38)
|
0.008
|
|
eGFR≥60 mL/min/1.73 m2
|
164/293 (56.0%)
|
103/219 (47.0%)
|
1.43 (1.01–2.04)
|
0.045
|
1.15 (0.68–1.95)
|
0.603
|
|
Heart disease
|
111/208 (53.4%)
|
156/304 (51.3%)
|
1.09 (0.76–1.55)
|
0.648
| | |
|
Chronic renal failure
|
47/116 (40.5%)
|
220/396 (55.6%)
|
0.55 (0.36–0.83)
|
0.004
|
0.62 (0.38–1.03)
|
0.062
|
|
Diabetes mellitus
|
58/112 (51.8%)
|
209/400 (52.3%)
|
0.98 (0.65–1.49)
|
0.931
| | |
|
Collagen disease
|
25/53 (47.2%)
|
242/459 (52.7%)
|
0.80 (0.45–1.42)
|
0.443
| | |
|
Chronic respiratory disease
|
14/27 (51.9%)
|
253/485 (52.2%)
|
0.99 (0.46–2.15)
|
0.975
| | |
|
Inflammatory bowel disease
|
44/89 (49.4%)
|
223/423 (52.7%)
|
0.88 (0.56–1.39)
|
0.573
| | |
|
Intensive care unit stay (> 3 days)
|
34/98 (34.7%)
|
233/414 (56.3%)
|
0.41 (0.26–0.65)
|
< 0.001
|
0.32 (0.19–0.56)
|
< 0.001
|
|
Liver cirrhosis/chronic hepatic dysfunction
|
34/72 (47.2%)
|
233/440 (53.0%)
|
0.80 (0.48–1.31)
|
0.367
| | |
|
Malignant tumor
|
99/204 (48.5%)
|
168/308 (54.5%)
|
0.79 (0.55–1.12)
|
0.182
| | |
|
Total parenteral nutrition
|
45/102 (44.1%)
|
222/410 (54.1%)
|
0.70 (0.43–1.03)
|
0.070
|
0.54 (0.32–0.92)
|
0.022
|
|
Serum albumin < 2.5 g/dL (median)
|
79/217 (36.4%)
|
188/295 (63.7%)
|
0.33 (0.23–0.47)
|
< 0.001
|
0.24 (0.15–0.37)
|
< 0.001
|
|
Ventilator use
|
37/90 (41.1%)
|
230/422 (54.5%)
|
0.58 (0.37–0.93)
|
0.021
|
1.51 (0.68–3.36)
|
0.316
|
|
Surgery within 28 days
|
68/158 (43.0%)
|
199/354 (56.2%)
|
0.59 (0.40–0.86)
|
0.006
|
0.47 (0.30–0.74)
|
0.001
|
|
Transplantation
|
6/8 (75.0%)
|
261/504 (51.8%)
|
2.79 (0.56–13.97)
|
0.289
| | |
|
Steroid use
|
42/85 (49.4%)
|
225/427 (52.7%)
|
0.88 (0.55–1.40)
|
0.580
| | |
|
Immunosuppressive therapy
|
18/28 (64.3%)
|
249/484 (51.4%)
|
1.70 (0.77–3.76)
|
0.186
| | |
|
Anticancer therapy
|
26/47 (55.3%)
|
241/465 (51.8%)
|
1.15 (0.63–2.10)
|
0.648
| | |
|
MRSA infections
|
72/139 (51.8%)
|
195/373 (52.3%)
|
0.98 (0.66–1.45)
|
0.923
| | |
|
Complicated MRSA infections
|
54/99 (54.5%)
|
213/413 (51.6%)
|
1.13 (0.73–1.75)
|
0.595
| | |
|
APACHE II score ≥ 15
|
54/130 (41.5%)
|
213/382 (55.8%)
|
0.56 (0.38–0.84)
|
0.005
|
0.78 (0.44–1.35)
|
0.371
|
- eGFR, estimated glomerular filtration rate, APACHE II Acute physiology and chronic health evaluation II score
